PLX Stock Analysis: Buy, Sell, or Hold?
PLX - Protalix BioTherapeutics, Inc. Common Stock
$2.15
-0.04 (-1.83%)
▼
5d:
+1.9%
30d:
-24.03%
90d:
+19.44%
BUY
MODERATE Confidence
Analysis Updated: Apr 2, 2026 12:00 AM ET
Earnings: May 08, 2026
Smart Money Accumulation
PLX is down 24.4% this week, but smart money is accumulating calls. Top strike: $2.5 2026-05-15 with 988 OI. Call ratio: 100% View Scanner →
Strength: 10.0/10
Get Alerted When PLX Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
💡 BUY OPPORTUNITY: PLX shows positive signals but monitor for confirmation. Market pricing in 9.2% growth. Moderate conviction.
💡 BUY OPPORTUNITY: PLX shows positive signals but monitor for confirmation. Market pricing in 9.2% growth. Moderate conviction.
In-depth Analysis How we analyze
Valuation Analysis: PLX is currently trading at $2.15, which is considered oversold relative to its 30-day fair value range of $2.19 to $2.93. From a valuation perspective, the stock is trading at a premium (Forward PE: 30.7) compared to its historical average (23.6). At these levels, the market is pricing in 9.2% annual earnings growth.
Technical Outlook: Technically, PLX is in a strong uptrend. Immediate support is located at $2.03, while resistance sits at $2.26.
Market Sentiment: PLX has a weak technical setup (25/100), with bearish trendlines and momentum suggesting caution for short-term entries. In the options market, Implied Volatility is low (22th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $11.00 (+411.6%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, PLX is in a strong uptrend. Immediate support is located at $2.03, while resistance sits at $2.26.
Market Sentiment: PLX has a weak technical setup (25/100), with bearish trendlines and momentum suggesting caution for short-term entries. In the options market, Implied Volatility is low (22th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $11.00 (+411.6%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
OVERSOLD
Fair Price Range
$2.19 -
$2.93
Company Quality Score
54/100
(HOLD)
Options IV Signal
22th percentile
(LOW)
Volume Confirmation
HIGH
Confidence Score
68.1%
All Signals
- BULLISH: Price oversold vs 30-day range
- BULLISH: Options cheap (IV 22th percentile)
- BEARISH: Weak technical setup (25/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 411.6% below Wall St target ($11.00)
- BULLISH: Expecting earnings turnaround to 9.2% growth with -49.9% revenue growth
Fair Price Analysis
30-Day Fair Range
$2.19 -
$2.93
Current vs Fair Value
OVERSOLD
Expected Move (7 Days)
±$0.30
(14.0%)
Support & Resistance Levels
Support Level
$2.03
Resistance Level
$2.26
Current Trend
Strong Uptrend
Technical data as of
Apr 2, 2026
Fundamental Context
Forward P/E (Next Year Est.)
30.71
Wall Street Target
$11.00
(+411.6%)
Revenue Growth (YoY)
-49.9%
Earnings Growth (YoY)
-1.0%
Profit Margin
-12.5%
Valuation Premium vs History
+9.2% premium
PE vs Historical
30.7 vs 23.6
STRETCHED
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
+9.2%
(market-implied from PE analysis)
1-Year Target
$2.35
(+9%)
2-Year Target
$2.56
(+19%)
3-Year Target
$2.80
(+30%)
3-Yr Target (if PE normalizes)
(PE: 31→24)
PE COMPRESSION
$2.15
(+0%)
Earnings growth offset by PE compression
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 30.7, Growth: -67.4%)
$1.57
(+-27%)
Base:
(SPY PE: 20.6, Growth: -67.4%)
$1.05
(-51%)
Bear:
(PE: 17.5, Growth: -67.4%)
$0.89
(-59%)
📈
Valuation based on Current Earnings
Trailing PE: 26.75 | Current EPS (TTM): $0.08
Bull Case
$2.06
(-3%)
Analyst growth -12.5%, PE expands to 29.4
Base Case
$1.87
(-12%)
Market implied -12.5%, PE stable at 26.8
Bear Case
$1.46
(-32%)
Severe decline -20.0%, PE contracts to 22.7
These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.
Share & Embed Analysis
Last updated: April 04, 2026 3:18 AM ET
Data refreshes hourly during market hours. Next update: 4:18 AM
Data refreshes hourly during market hours. Next update: 4:18 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is PLX showing a specific setup today?
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
ALNY
Alnylam Pharmaceuticals … |
STRONG BUY
33 analysts |
$449 | 58 HOLD |
|
IONS
Ionis Pharmaceuticals Inc |
BUY
26 analysts |
$94 | 56 HOLD |
|
DNLI
Denali Therapeutics Inc |
STRONG BUY
19 analysts |
$33 | 46 HOLD |
|
BBIO
BridgeBio Pharma Inc |
STRONG BUY
19 analysts |
$101 | 61 BUY |
|
ASND
Ascendis Pharma AS |
STRONG BUY
16 analysts |
$290 | 53 HOLD |
